已收盘 12-19 16:00:00 美东时间
0.000
0.00%
Cellectis reports a total of 100,325,229 shares and 89,110,384 voting rights as of May 31, 2025. Further details are available via the provided contacts.
06-05 20:30
Cellectis, a clinical-stage biotechnology company, announced the date and location of its upcoming 2025 annual general meeting on June 26 at 2:30 p.m. CET in Paris, France. The meeting details and board report are available on their website. Cellectis specializes in developing life-saving cell and gene therapies using its pioneering gene-editing platform.
05-21 20:30